Japan has a robust regulatory framework for pharmaceuticals and medical devices, supported by strict quality, safety, and compliance standards established under the Pharmaceuticals and Medical Devices Act and Japanese Good Clinical Practice (GCP) regulations. Foreign manufacturers and sponsors planning to conduct clinical trials in Japan must fulfil specific regulatory requirements, including appointing a Japan-based In-Country Clinical Caretaker (ICCC).
A Japan In-Country Clinical Caretaker plays a crucial role in helping foreign companies successfully conduct clinical trials by acting as the official representative between the sponsor, clinical trial sites, and the Pharmaceuticals and Medical Devices Agency (PMDA). The ICCC ensures that clinical trials comply with Japanese regulatory requirements, supports ectd regulatory submissions, manages communication with authorities, and helps maintain compliance throughout the clinical development process.
Need Clinical Regulatory Support for Trials in Japan?
Navigate Japan's clinical trial requirements with DDReg Pharma's expert support for PMDA submissions, Clinical Trial Notifications, regulatory strategy, authority interactions, and in-country regulatory support.
Explore Clinical Regulatory Services →What Is a Clinical Trial In-Country Representative (ICCC) in Japan?
An In-Country Clinical Caretaker (ICCC), also known as a Clinical Trial In-Country Representative, is a Japan-based representative appointed by a foreign sponsor conducting clinical trials in Japan without an established local entity.
The ICCC acts as the official intermediary between the foreign sponsor and PMDA. Their role is to ensure that clinical trial activities comply with Japanese regulations and that sponsor responsibilities are properly managed according to Japan’s GCP requirements.
For foreign companies entering the Japanese market, appointing the right Japan In-Country Clinical Caretaker is essential for effective regulatory communication, clinical trial oversight, and successful market access.
What are the Key Responsibilities of a Japan ICCC?
What Is a Japan Clinical Trial Notification (CTN)?
A Clinical Trial Notification is a regulatory notification submitted in connection with the planned conduct of a clinical trial in Japan. PMDA’s current notification materials include information about the clinical trial, sponsor/notifier, study product, medical institutions, investigators, and the clinical trial in-country representative, among other information.
Complements of CTN Information
Information | Examples |
Study information | Clinical trial identification and objective |
Investigational product | Generic name, characteristics and manufacturing information |
Protocol | Clinical trial plan |
Investigators | Investigator information |
Sites | Medical institution information |
Sponsor | Foreign sponsor information |
Local representative | Clinical trial in-country representative |
Outsourced activities | Contractor and scope of activities |
How Does the Japan Clinical Trial In-Country Representative Process Work?
The Japan ICCC process involves multiple stages, from sponsor appointment to ongoing clinical trial management.
- ICCC Appointment –Foreign sponsors must first select a Japan-based ICCC that is qualified to perform sponsor-related obligations in Japan. The sponsor and ICCC define roles, communication procedures, and regulatory responsibilities before the clinical trial begins.
- Regulatory Planning and PMDA Consultation –Before starting a clinical trial, the ICCC supports regulatory planning and participates in PMDA Regulatory consultations. This helps sponsors understand Japan-specific requirements and develop an appropriate clinical development strategy.
- Japan Clinical Trial Notification Submission –The ICCC prepares and submits the Clinical Trial Notification to PMDA along with all required documents. Following submission, the ICCC manages communication with PMDA and supports responses to regulatory queries.
- Trial Conduct and Monitoring –During the clinical trial, the ICCC coordinates with foreign sponsors, clinical trial sites, investigators, CRO partners, and regulatory authorities. It ensures that trial activities are conducted according to the approved protocol and Japanese GCP requirements.
- Ongoing Regulatory and Safety Management –Throughout the trial, the ICCC manages ongoing regulatory and safety requirements, including safety reporting, protocol amendments, Investigator’s Brochure updates, regulatory communications, and compliance documentation.
Need Pharmacovigilance Support for Japan Clinical Trials?
Strengthen safety compliance in Japan with support for ICSR processing, adverse event reporting, signal management, risk management plans, and PMDA pharmacovigilance requirements.
Explore Japan Pharmacovigilance Services →Japan ICCC Safety Reporting: SAE, Individual Cases & Safety Management Plan
Safety management is one of the most important responsibilities of a Japan In-Country Clinical Caretaker. The ICCC ensures that safety information is properly collected, reviewed, assessed, and reported according to Japanese regulatory requirements.
For foreign sponsors conducting clinical trials in Japan, effective ICCC safety reporting processing is essential to protect trial participants and maintain compliance with PMDA expectations.
- Serious Adverse Event (SAE) Reporting –The ICCC supports the management of Serious Adverse Events (SAEs) reported during clinical trials. Key responsibilities include:
- Receiving safety reports from investigators
- Reviewing SAE documentation
- Communicating safety information with sponsors
- Ensuring timely regulatory reporting
- Maintaining safety records
The ICCC works closely with sponsors, investigators, and CRO partners to ensure that safety information is appropriately evaluated and handled throughout the clinical trial lifecycle.
- Regulatory submission when required Individual Case Safety Reports (ICSRs) – The ICCC also supports the management of Individual Case Safety Reports by ensuring:
- Accurate adverse event documentation
- Medical review and assessment
- Appropriate classification of safety events
- Regulatory submission when required Individual Case Safety Reports (ICSRs) – The ICCC also supports the management of Individual Case Safety Reports by ensuring:
For global clinical trials, coordination among sponsors, CROs, investigators, and ICCCs is essential to maintain consistent safety management practices.
- Safety Management Plan Japan – A Safety Management Plan Japan defines how safety information is collected, monitored, evaluated, and communicated during clinical development. The ICCC supports safety management by:
- Establishing safety reporting procedures
- Monitoring adverse event trends
- Supporting risk evaluation activities
- Ensuring compliance with PMDA requirements
- Maintaining safety documentation
A structured safety signal management plan approach helps sponsors identify potential risks early and maintain regulatory compliance throughout clinical development
Clinical Trial In-Country Representative vs CRO: What Is the Difference?
Foreign sponsors often work with both an ICCC and a Contract Research Organization (CRO) when conducting clinical trials in Japan. While both support clinical development activities, their responsibilities are different.
ICCC | CRO |
Represents the foreign sponsor in Japan | Provides outsourced clinical trial services |
Handles sponsor-related regulatory obligations | Supports operational trial activities |
Acts as a communication channel with PMDA | Performs monitoring, data management, and site activities |
Supports Japan Clinical Trial Notification submission | Supports trial execution |
Oversees regulatory compliance | Manages clinical operations |
Many sponsors choose a Japan ICCC CRO solution where a single partner provides both regulatory representation and clinical trial support.
This approach can simplify communication, improve compliance, and reduce operational complexity for foreign sponsors entering the Japanese market.
What Should You Check Before Selecting a Japan In-Country Representative?
Choosing the right Japan In-Country Representative is essential for ensuring regulatory compliance and smooth clinical trial operations.
Factor | What to Evaluate |
PMDA experience | Experience with applicable Japanese procedures |
Local presence | Japan-based regulatory capability |
Clinical-trial knowledge | Understanding of GCP and trial requirements |
Regulatory communication | Ability to manage authority interactions |
Safety capability | Experience with applicable safety obligations |
Documentation | Quality of regulatory documentation management |
CRO coordination | Ability to coordinate with external CROs |
Continuity | Availability throughout the clinical trial lifecycle |
Why Do Foreign Sponsors Need Local Regulatory Support in Japan?
Foreign sponsors need local regulatory support in Japan because navigating Japanese clinical trial requirements involves local regulations, regulatory communications, documentation, and operational expectations.
- Local Regulatory Requirements: Helps foreign sponsors understand and comply with Japan-specific clinical trial regulations.
- Japanese GCP: Ensures trial activities follow Japanese Good Clinical Practice (GCP) requirements.
- PMDA Interactions: Supports effective communication and coordination with the PMDA.
- CTN: Helps manage Clinical Trial Notification (CTN) requirements and submissions.
- Local Representation: Provides the required local support and regulatory representation for foreign sponsors.
- Safety Obligations: Ensures timely and compliant safety reporting throughout the trial.
- Japanese Documentation: Supports preparation, review, and maintenance of required Japanese regulatory documents.
- Sponsor Responsibilities: Helps foreign sponsors fulfill their regulatory and operational responsibilities in Japan.
Conclusion
Japan’s regulatory framework ensures high standards of safety, quality, and effectiveness for pharmaceutical and medical device products. For foreign sponsors conducting clinical trials in Japan, appointing a qualified Japan In-Country Clinical Caretaker is a key requirement for successful regulatory navigation.
From Japan Clinical Trial Notification submission and PMDA communication to ICCC safety reporting and compliance management, the ICCC provides essential local regulatory support. Understanding the responsibilities of an ICCC, the difference between ICCC and CRO services, and the importance of safety management planning allows international companies to confidently enter the Japanese clinical research market.
How Can DDReg Support Foreign Sponsors with Japan Clinical Trials?
DDReg has provided its customers with end-to-end regulatory affairs services to support successful market access and post-approval life cycle management for their products with the Japan PMDA.
Our regulatory experts support companies with:
- Japan ICCC services
- PMDA regulatory support
- Japan Clinical Trial Notification assistance
- Clinical trial regulatory strategy
- Safety reporting management
- Regulatory compliance support
- Post-approval lifecycle management
With expertise in global regulatory requirements, DDReg helps companies navigate complex regulatory pathways and achieve successful product approvals.